

DIGIVAL

Rapid, objective, accurate.





WORKFLOW FLEXIBILITY

Read Now or Walk-Away, DIGIVAL provides the flexibility to suit your workflow and throughput.



OBJECTIVE RESULTS

DIGIVAL eliminates operator subjectivity and is designed to provide consistency in the reading of lateral flow test assays.



FLEXIBLE ACCESS

Save your results on DIGIVAL, share them with the LIMS/HIS or print them right at the point-of-care. With DIGIVAL, it's up to you.



EASY-TO-USE

Just scan the device barcode, enter the patient ID, and place the test device into DIGIVAL. The results are displayed on a colour LCD display.



RAPID RESULTS

DIGIVAL combines the control of a connected instrument with the speed of a rapid lateral flow assay.



BARCODE TECHNOLOGY

Maximize accuracy and minimize human error. The barcode scanner allows the user to quickly enter and connect patient ID and test information.



ENHANCED QUALITY CONTROL

For complete confidence in the assay results, DIGIVAL has a Quality Control module and a QC lockout feature to ensure quality controls are tested.

DIGIVAL currently supports the following tests:

BINAXNOW" S. PNEUMONIAE AND LEGIONELLA

BinaxNOW *S. pneumoniae* and *Legionella* tests can provide sensitive and accurate results from a urine sample with immediate answers, enabling physicians to prescribe narrow-spectrum targeted treatment sooner.

■ Results: 15 minutes

■ Sample type: Urine and CSF (S. pneumoniae only)

CAP GUIDELINES

Recommended by the BTS guidelines, ERS/ESCMID guidelines, SEPAR and NICE guidance.¹⁻⁴

Access to timely information enables targeted treatment decisions.



Why use DIGIVAL?

VISUAL INTERPRETATION VS. DIGIVAL



How many test lines can you identify on this calibration card?





DIGIVAL can detect 10 lines.

Enhanced image to depict the DIGIVAL "view."



AVAILABLE TESTS

BINAXNOW[®] S. PNEUMONIAE TEST

BINAXNOW^{*} LEGIONELLA TEST

ORDERING INFORMATION

PRODUCT NAME	PRODUCT CODE
DIGIVAL™ BINAXNOW™ COMPLETE KIT	LFR-100
Martel Thermal Printer	MCP1810395
Replacement Printer Paper	GP15
BINAXNOW™ S. PNEUMONIAE	
12 Test Kit	710-012
22 Test Kit	710-100
Control swabs - 5 positive and 5 negative swabs	710-010
BINAXNOW™ <i>LEGIONELLA</i>	
12 Test Kit	852-012
22 Test Kit	852-100
Control swabs - 5 positive and 5 negative swabs	852-010

ANTIMICROBIAL STEWARDSHIP

Antimicrobial resistance is a huge global health issue and contributes significantly to patient mortality and healthcare costs across the world.⁵

An accurate diagnosis of CAP is most important to avoid inappropriate antibiotics, to limit drug costs, and reduce the threat of antibiotic resistance and *C. difficile*-associated diarrhea.¹

The Test Target Treat™ initiative from Abbott empowers healthcare professionals to make targeted treatment decisions sooner with rapid diagnostics—reducing inappropriate antimicrobial misuse and the spread of resistance.

- 1. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009
- $2.\ ERS/ESCMID\ guidelines: https://www.escmid.org/fileadmin/src/media/PDFs/4ESCMID_Library/2Medical_Guidelines/ESCMID_Guidelines/Woodhead_et_al_CMI_Sep_2011_LRTI_GL_summary.pdf$
- 3. Normativas para el diagnóstico y el tratamiento de la neumonia adquirida en la comunidad, Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR)
- $4. \ \ NICE\ guidelines, 2014.\ https://www.nice.org.uk/guidance/cg191\ (accessed\ Jan\ 15, 2015)$
- $5. \ \ The \ review \ on \ antimicrobial \ resistance \ 2016; https://amr-review.org/Publications.html$



TARGET